Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and methods for inhibiting the activation of dsRNA-dependent protein kinase and tumor growth inhibition

A technology of protein kinases and compositions, applied in the direction of antineoplastic drugs, drug combinations, active ingredients of heterocyclic compounds, etc.

Inactive Publication Date: 2010-10-20
NESTEC SA
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Nutritional supplements that help restore muscle mass loss in cancer or any diseased host remain largely ineffective

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for inhibiting the activation of dsRNA-dependent protein kinase and tumor growth inhibition
  • Compositions and methods for inhibiting the activation of dsRNA-dependent protein kinase and tumor growth inhibition
  • Compositions and methods for inhibiting the activation of dsRNA-dependent protein kinase and tumor growth inhibition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0155] The disclosure is further defined in the following examples. It should be understood that, while indicating preferred embodiments, these Examples are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the preferred characteristics of this disclosure, and without departing from the spirit and scope thereof, can make various changes and modifications to adapt it to various usages and conditions.

[0156] Material

[0157] Fetal calf serum (FCS) and RPMI 1640 tissue culture medium were purchased from Invitrogen (Paisley, Scotland). L-[2,6- 3 H] phenylalanine (spec, act., 2.00TBqmmol -1 ), Hybond A nitrocellulose membrane and enhanced chemiluminescence (ECL) development kit were obtained from Amersham Biosciences (Bucks, UK). Antiphosphorabbit monoclonal antibodies and total PKR were purchased from New England Biolabs (Herts, UK). Rabbit polyclonal antiserum against phospho-eIF2α was obtained from Abcam...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to compositions and methods for preventing and treating a condition in a mammalian subject that include at least one inhibitor of double stranded RNA dependent protein kinase (PKR-I) prior to or concurrently with the treatment, wherein the treatment results to an inhibition of activation of dsRNA-dependent protein kinase. The compositions and methods of the present invention further include at least one potentiator that further enhances the inhibition of phosphorylation by PKR-I.

Description

technical field [0001] The present invention relates to compositions and methods for the prophylaxis and treatment of diseases in mammalian individuals comprising at least one double-stranded RNA-dependent protein kinase inhibitor (PKR-I) administered prior to or concurrently with the treatment, wherein the treatment results in inhibition of activation of the dsRNA-dependent protein kinase. The compositions and methods of the invention also include at least one potentiator, which further enhances inhibition of PKR-I phosphorylation. Background technique [0002] Cachexia is often associated with a variety of disease states, including acute inflammatory processes associated with severe disease and chronic inflammatory diseases such as cancer, sepsis, congestive heart failure, rheumatoid arthritis, chronic obstructive pulmonary disease, and human immunodeficiency Viral infection. It is also associated with other known muscle-wasting diseases and conditions, eg, sarcopenia, s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/429A61P17/00A61P9/04A61P3/10A61P1/14A61K31/52A61K31/553A61K31/198A61K45/06A23L1/305A61P35/00A61P31/18A61P29/00A61P25/28A61P19/02
CPCA61K31/198A61K31/553A61K31/429A61K41/00A23L1/3012A61K31/52A61K45/06A23L33/13A61P1/00A61P1/04A61P1/14A61P1/16A61P11/00A61P13/12A61P17/00A61P19/00A61P19/02A61P25/04A61P25/20A61P25/28A61P29/00A61P3/00A61P31/00A61P31/04A61P31/18A61P35/00A61P37/00A61P37/02A61P43/00A61P9/00A61P9/04A61P9/10A61P3/10A61K2300/00
Inventor M·J·提斯达尔H·L·埃雷S·T·拉塞尔K·B·米勒
Owner NESTEC SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products